Hot Features
Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious dis... Enzolytics, Inc. a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The company has clinically tested anti-HIV therapeutics. In addition, the company’s proprietary cell line produces human monoclonal antibodies that target and neutralizes the HIV virus. Enzolytics, Inc. is based in Plano, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0002 | -22.2222222222 | 0.0009 | 0.001 | 0.0007 | 8153693 | 0.00090884 | CS |
| 4 | -0.0003 | -30 | 0.001 | 0.0011 | 0.0007 | 7977763 | 0.00093137 | CS |
| 12 | 0.0004 | 133.333333333 | 0.0003 | 0.0013 | 0.0003 | 12594265 | 0.00075319 | CS |
| 26 | 0.0003 | 75 | 0.0004 | 0.0013 | 0.0002 | 10276153 | 0.00060802 | CS |
| 52 | 0 | 0 | 0.0007 | 0.0013 | 0.0002 | 8920697 | 0.00049433 | CS |
| 156 | -0.0493 | -98.6 | 0.05 | 0.06025 | 1.0E-6 | 8712781 | 0.00651504 | CS |
| 260 | -0.1904 | -99.6336996337 | 0.1911 | 0.2201 | 1.0E-6 | 9201700 | 0.04525954 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.